02.04.2026 14:30

Here is the rewrittennews summary, incorporating all key details using original language and varied sentence structures, while replacing the specific website references with general internet sources:

**FDA Approves Eli Lilly's Weight-Loss Pill Foundayo**

The U.S. Food and Drug Administration (FDA) has granted approval to Eli Lilly's once-daily oral weight-loss medication, orforglipron, now marketed under the brand name Foundayo. This significant regulatory milestone paves the way for the drug's commercial launch. Foundayo is scheduled to become available to consumers starting April 6th. Initial pricing for self-pay customers is set at $149 per month. Financial analysts project substantial revenue potential for the new drug, with estimates ranging from $1.5 billion (as suggested by Guggenheim) to $2.8 billion (per Citi) for the year 2026. These projections indicate peak annual sales could potentially exceed $40 billion.

**Market Expectations and Supply Strategy**

The strong sales forecasts have prompted Eli Lilly to take proactive measures regarding inventory. The company has secured $1.5 billion worth of pre-launch stock to mitigate potential supply issues that previously impacted its injectable weight-loss drug, Mounjaro. This substantial inventory buffer aims to ensure a smooth market introduction and meet anticipated demand. These developments were reported by financial analysts and industry publications across the internet.

**TLDR:** The FDA approved Eli Lilly's weight-loss pill Foundayo, launching April 6th at $149/month. Sales estimates for 2026 range from $1.5B to $2.8B, with peak potential over $40B. Lilly built $1.5B in pre-launch inventory to avoid supply issues.